When was Daré Bioscience founded?

Daré Bioscience was founded in 2005 and raised its 1st funding round 12 years after it was founded.

Where is Daré Bioscience located?

Daré Bioscience is headquartered in San Diego, United States.

How many employees does Daré Bioscience have?

As of Mar 31, 2026, the latest employee count at Daré Bioscience is 25.

Is Daré Bioscience a funded company?

Daré Bioscience is a funded company, having raised an undisclosed amount across 18 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Jul 19, 2017.

When was the latest funding round of Daré Bioscience?

Daré Bioscience's latest funding was a $***** Grant (prize money) round on Nov 24, 2025, with participation from 1 investor.

What is the annual revenue of Daré Bioscience?

Annual revenue of Daré Bioscience is $1.03M as on Dec 31, 2025.

Where does Daré Bioscience rank among its competitors?

Daré Bioscience ranks 7th amongst 57 active competitors, of which 12 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Valanx Biotech, which secured $3.48M in Mar, 2026.

Who are the top competitors of Daré Bioscience?

Daré Bioscience's top competitors include Olema Oncology, Minerva Biotechnologies and Femasys. Among them, Valanx Biotech secured the most recent funding round in March, 2026.

Daré Bioscience - 2026 Company Profile, Funding, Competitors & Financials

Daré Bioscience is a public company based in San Diego (United States), founded in 2005. It operates as a Developer of non-hormonal pharmaceutical products for female contraceptives. Daré Bioscience has raised an undisclosed amount in funding. The company has 57 active competitors, including 12 funded and 13 that have exited. Its top competitors include companies like Olema Oncology, Minerva Biotechnologies and Femasys.

Company Details

DARE BIOSCIENCE is a developer of non-hormonal pharmaceutical products for female contraceptives. Their lead candidate, Ovaprene, is an intravaginal non-hormonal ring, that can provide contraceptive protection over several weeks. The design of the ring has a permeable mesh in the centre of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The spermiostatic agents are ascorbic acid and ferrous gluconate, which create pH buffering and immobilization of sperm.

Website: darebioscience.com
Social
Email ID: *****@darebioscience.com
Phone Number: +1 **********

Key Metrics

Founded Year

2005

Location

San Diego, United States

Stage

Public

Latest Funding Round

Grant (prize money), Nov 24, 2025, $*****

Investors

NIH & 3 more

Ranked

7^th among 57 active competitors

Annual Revenue

$1.03M as on Dec 31, 2025

Employee Count

25 as on Mar 31, 2026

Investment & Acquisitions

Microchips Biotech & 1 more

Similar Companies

Olema Oncology & 64 more

Exit Details

Public

View Daré Bioscience's full profile

Daré Bioscience is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
DARE BIOSCIENCE, INC. CIN: 1401914 , United States, Active	Nov 27, 2005	$1.03M (As on Dec 31, 2025)	30 (As on Dec 31, 2023)	-
DARE BIOSCIENCE, INC CIN: 4067151 , United States, Active	Nov 27, 2005	-	27 (As on Dec 31, 2021)	-

Daré Bioscience got listed on Apr 14, 2014.

Click here to take a look at Daré Bioscience's IPO in detail

Daré Bioscience has raised funding over 18 rounds. Its first funding round was on Jul 19, 2017. Its latest funding round was a Grant (prize money) round on Nov 24, 2025 for $*****. 1 investor participated in its latest round. Daré Bioscience has 4 institutional investors.

Here is the list of recent funding rounds of Daré Bioscience:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 24, 2025	3653120	Grant (prize money)	4235928	6251253	8061328	8076879
Feb 20, 2025	2147443	Grant (prize money)	9436829	1659063	8802304	HHS
Dec 17, 2024	3334626	Grant (prize money)	4643475	3431032	4316978	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Daré Bioscience's funding rounds and investors

Daré Bioscience's employee count trend

Daré Bioscience has 25 employees as of Mar 26. Here is Daré Bioscience's employee count trend over the years:

Employee count trend for Daré Bioscience

Uncover Daré Bioscience's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Daré Bioscience include Olema Oncology, Minerva Biotechnologies and Femasys. Here is the list of Top 10 competitors of Daré Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Olema Oncology 2007, San Francisco (United States), Public	Provider of drug therapeutics for breast cancer treatment	$139M	BVF Partners, Logos & 17 others	61/100
2nd	Minerva Biotechnologies 1999, Waltham (United States), Early Stage	Developer of cell therapy and antibodies to treat cancer	$18.9M	Springboard Enterprises, HHS	59/100
3rd	Femasys 2004, Atlanta (United States), Public	Developer of medical device solutions for womens healthcare	$69.2M	Legacy Capital, Salem Partners & 2 others	56/100
4th	Greenwich LifeSciences 2019, Houston (United States), Public	Developer of peptide-based immunotherapy for cancer treatment	-	-	54/100
5th	Puma Biotechnology 2010, Los Angeles (United States), Public	Developer of tyrosine kinase inhibitor for the treatment of breast cancer	$60M	Athyrium Capital Management, BB Biotech & 4 others	53/100
6th	Valanx Biotech 2017, Graz (Austria), Series A	Develops tools for protein conjugation	$6.19M	tecnet equity, SOSV & 6 others	52/100
7th	Daré Bioscience 2005, San Diego (United States), Public	Developer of non-hormonal pharmaceutical products for female contraceptives	-	NIH, Gates Foundation & 2 others	58/100
8th	ExpreS2ion Biotechnologies 2010, Copenhagen (Denmark), Public	Provider of recombinant protein production using an insect expression platform	-	Modelio Equity, Gemstone Capital & 2 others	48/100
9th	Atossa Therapeutics 2009, Seattle (United States), Public	Developer of drugs for treating breast cancer	$6.77M	Keiretsu Forum	47/100
10th	PIQUR 2011, Basel (Switzerland), Series A	Developer of anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition	$60M	Versant Ventures, Eurostars & 1 others	45/100